The Per-protocol Population (PP) includes subjects who received any dose of BGB-A317 and had no major protocol deviations. Criteria for exclusion from the PP will be determined and documented before the database lock for the primary analysis. This will be the secondary analysis population for efficacy analysis. The PK population includes all subjects who whom valid BGB-A317 PK parameters can be estimated.